Buy 1 Artificial Intelligence (AI) Stock With More Upside Than Palantir, According to Wall Street Analysts

The article is constructive on both Palantir and Axon, highlighting Palantir's 70% revenue growth to $1.4B and Axon's 39% sales increase to $797M, alongside strong AI product integration at both companies. Wall Street targets imply 40% upside for Palantir and 76% upside for Axon, though Palantir's 190x adjusted earnings valuation is flagged as expensive. Overall, the piece is a bullish stock-picking commentary rather than a market-moving event.

Analysis

The market is rewarding both names for being category-defining, but the durability of that premium depends on whether AI is monetized as a productivity layer or becomes a procurement line item. PLTR is the cleaner pure-play on workflow re-engineering, but that also makes it the more fragile multiple: when a software platform trades at triple-digit earnings, any slowdown in deal conversion or government budget timing can compress the stock faster than fundamentals deteriorate. AXON has a better “pick-and-shovel” profile because AI features are attached to must-buy hardware and compliance workflows, which lowers adoption friction and makes monetization less dependent on discretionary software expansion.

The second-order read-through is that both companies are using AI to pull forward demand from adjacent incumbents. For PLTR, the threat is less traditional software and more internal BI, data engineering, and systems integrator spend getting cannibalized; for AXON, the real displacement is manual back-office labor, evidence management vendors, and legacy CAD/RMS workflows. That creates a longer runway than headline growth implies, but the near-term market error is likely to be in margin assumptions: AI features can accelerate win rates before they meaningfully expand gross profit if compute, support, and implementation costs rise with usage.

Catalyst timing matters. Over the next 1-3 quarters, AXON’s backlog and attachment rates should matter more than revenue prints because the stock is implicitly paying for multi-year conversion, while PLTR’s valuation leaves little room for execution hiccups even if growth stays strong. The contrarian point is that the “obvious” winner may be the less crowded one: AXON’s AI is easier to justify inside budgets because it is tied to officer time saved and evidence defensibility, whereas PLTR still needs continued proof that ontology-based workflows can scale beyond flagship deployments without becoming services-heavy.

The main risk to both is that AI enthusiasm causes investors to extrapolate product novelty into permanent growth, when the real test is retention and expansion after the initial pilot cycle. If enterprise spending tightens, PLTR’s premium multiple is vulnerable first; if public-sector procurement slows, AXON’s growth can stay resilient longer because safety budgets are stickier. In both cases, the next leg should be driven less by product announcements and more by whether customer cohorts are expanding consumption 6-12 months after launch.

Key Decisions for Investors

• Long AXON vs. short PLTR as a relative-value pair for the next 3-6 months: AXON has a better earnings-quality profile and less multiple fragility, while PLTR is already discounting near-perfect execution.
• Buy AXON on pullbacks or via call spreads expiring in 6-9 months to express upside from backlog conversion; target a 2:1 reward/risk if the market starts capitalizing recurring software revenue more like infrastructure than SaaS.
• Avoid chasing PLTR into strength; if already long, trim into rallies and re-enter only after the next earnings cycle confirms that growth is still broadening without margin dilution.
• For event-driven exposure, consider AXON May/June call spreads into the next quarter if booking momentum remains strong; the setup is better for incremental rerating than PLTR because expectations are less saturated.
• If you want asymmetric downside protection on AI sentiment, hedge any PLTR long with short-dated puts around earnings; the stock’s valuation leaves it most exposed to even a small miss in growth or guidance.